Studies in preclinical mouse models showed that the pharmacological blockade of IL-6 suppresses progression of KRAS-mutant positive lung cancer, inhibits STAT3 activation and more importantly diminishes the number of pro-tumor M2 macrophages, MDSCs and Treg cells while the CD8+ T-cell responses increases (Caetano et al., 2016, Figure 2A). This evidence concerns the gene IL6 and lung carcinoma.